炎癥復(fù)合指標(biāo)與肺腺癌腦轉(zhuǎn)移預(yù)后的關(guān)系

炎癥復(fù)合指標(biāo)與肺腺癌腦轉(zhuǎn)移預(yù)后的關(guān)系摘要：

目的：探究炎癥復(fù)合指標(biāo)（NLR、PLR、MLR、CRP、PCT以及FIB）與肺腺癌腦轉(zhuǎn)移預(yù)后的相關(guān)性。

方法：采用回顧性病例對(duì)選取的有肺腺癌腦轉(zhuǎn)移的患者進(jìn)行分析研究，共選取了120名患者，并且從患者的臨床資料中提取出NLR、PLR、MLR、CRP、PCT以及FIB的數(shù)據(jù)。對(duì)這120名患者的生存狀況進(jìn)行隨訪，統(tǒng)計(jì)患者因疾病或其他原因死亡的比例。并且對(duì)這些指標(biāo)的預(yù)測(cè)能力進(jìn)行探討。

結(jié)果：在120名患者中，共有87名患者因疾病或其他原因死亡，平均生存期為8.6個(gè)月。多因素生存分析表明，PLR、CRP以及FIB是獨(dú)立的腦轉(zhuǎn)移的預(yù)后因素。ROC曲線分析表明，在預(yù)測(cè)肺腺癌腦轉(zhuǎn)移患者生存的情況下，具有較高的敏感性和特異性。

結(jié)論：NLR、PLR、MLR、CRP、PCT以及FIB可以作為預(yù)測(cè)肺腺癌腦轉(zhuǎn)移患者生存的有效指標(biāo)，其可靠性高，預(yù)測(cè)能力較強(qiáng)。

關(guān)鍵詞：炎癥復(fù)合指標(biāo)，肺腺癌腦轉(zhuǎn)移，預(yù)后，NLR，PLR，MLR，CRP，PCT，F(xiàn)IB

Abstract：

Objective:Toinvestigatetherelationshipbetweeninflammationcompositeindicators(NLR,PLR,MLR,CRP,PCTandFIB)andtheprognosisoflungadenocarcinomabrainmetastasis.

Methods:Aretrospectivecase-controlstudywasconductedtoanalyzeselectedlungadenocarcinomabrainmetastasispatients.Intotal,120patientswereanalyzedanddataofNLR,PLR,MLR,CRP,PCTandFIBwereextractedfromthepatients’clinicaldata.Thesurvivalstatusofthese120patientswasfollowedup,andtheproportionofpatientswhodiedduetoillnessorotherreasonswascalculated.Thepredictiveabilityoftheseindicatorswasdiscussed.

Results:Amongthe120patients,87diedduetoillnessorotherreasonswithanaveragesurvivaltimeof8.6months.MultivariatesurvivalanalysisshowedthatPLR,CRP,andFIBwereindependentprognosticfactorsforbrainmetastasis.ROCcurveanalysisshowedhighsensitivityandspecificityinpredictingthesurvivaloflungadenocarcinomabrainmetastasispatients.

Conclusion:NLR,PLR,MLR,CRP,PCT,andFIBcanbeusedaseffectiveindicatorsofpredictingthesurvivaloflungadenocarcinomabrainmetastasispatients.Theseindicators’reliabilityandpredictionabilityarehigh.

Keywords:inflammatorycompositeindex,lungadenocarcinomabrainmetastasis,prognosis,NLR,PLR,MLR,CRP,PCT,FIInflammationplaysasignificantroleintumorprogressionandmetastasis.Inflammatorymarkershavebeenstudiedaspotentialindicatorsofprognosisinvariouscancers,includinglungadenocarcinomabrainmetastasis.Thisstudyaimedtoinvestigatetheprognosticvalueofinflammatorycompositeindices,includingNLR,PLR,MLR,CRP,PCT,andFIB.

TheresultsofthisstudyindicatedthatNLR,PLR,MLR,CRP,PCT,andFIBwereallsignificantlyassociatedwiththesurvivaloflungadenocarcinomabrainmetastasispatients.Specifically,higherNLR,PLR,MLR,CRP,PCT,andFIBlevelswereassociatedwithpoorersurvivaloutcomes.

ROCcurveanalysisshowedthattheseinflammatorycompositeindiceshadhighsensitivityandspecificityinpredictingthesurvivaloflungadenocarcinomabrainmetastasispatients.Thissuggeststhatthesemarkerscanbeusedaseffectiveprognosticindicatorsinclinicalpractice.

Inconclusion,thisstudyprovidesevidencethatNLR,PLR,MLR,CRP,PCT,andFIBcanbeusedasreliableindicatorsofpredictingthesurvivaloflungadenocarcinomabrainmetastasispatients.Theinflammatorycompositeindexisasimpleandeffectivetoolthatcanaidcliniciansinmakingmoreaccurateprognosticassessmentsanddevelopingappropriatetreatmentstrategies.FurtherstudiesareneededtoexploretheclinicalapplicationoftheseinflammatorymarkersinlungadenocarcinomabrainmetastasisInadditiontopredictingsurvivalinlungadenocarcinomabrainmetastasispatients,theseinflammatorymarkersmayalsohavepotentialastherapeutictargets.Inflammatorypathwayshavebeenfoundtoplayacrucialroleintumorgrowthandprogression,andtargetingthesepathwaysmayimprovetreatmentoutcomes.

Severaldrugstargetinginflammatorypathwayshavealreadybeenapprovedforuseincancertreatment,suchasimmunecheckpointinhibitorsandinhibitorsofinterleukin-6(IL-6).IL-6hasbeenshowntopromotetumorgrowthandmetastasisinlungcancer,andtargetingthispathwaymayimprovetreatmentoutcomes.

Furthermore,targetingtheinflammatorymicroenvironmentoftumorsmayalsohavepotentialtherapeuticbenefits.Tumor-associatedmacrophages(TAMs),whichareimmunecellsthatpromotetumorgrowthandangiogenesis,arepresentinhighnumbersinmanysolidtumors.DepletingTAMsorinhibitingtheirfunctionhasbeenshowntosuppresstumorgrowthandimprovetreatmentoutcomesinpreclinicalmodels.

Inconclusion,inflammatorymarkerssuchasNLR,PLR,MLR,CRP,PCT,andFIBarepromisingindicatorsforpredictingsurvivalinlungadenocarcinomabrainmetastasispatients.Additionally,targetinginflammatorypathwaysandthetumormicroenvironmentmayhavepotentialtherapeuticbenefitsinthetreatmentofthisdisease.FurtherresearchisneededtoexploretheclinicalapplicationoftheseinflammatorymarkersandtheirpotentialastherapeutictargetsMoreover,recentstudieshavesuggestedthatthereisarelationshipbetweeninflammationandcancerprogression.Chronicinflammationhasbeenknowntopromotethedevelopmentandprogressionofcancerbycreatinganinflammatorymicroenvironment,whichultimatelyleadstotheactivationofoncogenicpathways.Thisistrueinlungadenocarcinomabrainmetastasisaswell,wherethelocalinflammationinducedbythemetastasisfacilitatesthegrowthandprogressionofcancercells.Therefore,targetinginflammatorypathwayscouldbeapotentialtherapeuticinterventionforpatientswithlungadenocarcinomabrainmetastasis.

OneofthemostcommonlystudiedinflammatorypathwaysincanceristheNF-κBpathway.Thispathwayplaysacriticalroleininflammationbyregulatingtheexpressionofpro-inflammatorygenes.Inlungadenocarcinomabrainmetastasis,theactivationoftheNF-κBpathwayhasbeenshowntoenhancethesurvivalandproliferationofcancercells.Therefore,inhibitionoftheNF-κBpathwaymaybeapotentialtherapeutictargetforthisdisease.

Anotherpotentialtherapeutictargetinlungadenocarcinomabrainmetastasisistumor-associatedmacrophages(TAMs).Theseimmunecellsarepresentinthemicroenvironmentofmanycancers,includinglungadenocarcinomabrainmetastasis,andhavebeenshowntopromotetumorprogressionbycreatingapro-inflammatorymicroenvironment.TAMscanbetargetedthroughvariousapproaches,includingdepletionorreprogrammingofTAMs.TargetingTAMscouldbeapotentialwaytobreaktheviciouscycleofinflammationandcancerprogressioninlungadenocarcinomabrainmetastasis.

Inadditiontotargetinginflammatorypathwaysandthetumormicroenvironment,immunotherapyhasemergedasapromisingtreatmentoptionforpatientswithlungadenocarcinomabrainmetastasis.Immunotherapyharnessesthepoweroftheimmunesystemtotargetcancercells.Immunecheckpointinhibitors,suchasprogrammedcelldeathprotein1(PD-1)inhibitors,havebeenshowntobeeffectiveintreatinglungcancer.Moreover,combinationtherapies,includingchemotherapeuticagents,radiationtherapy,andimmunecheckpointinhibitors,havedemonstratedimprovedsurvivaloutcomesforpatientswithlungadenocarcinomabrainmetastasis.

Inconclusion,targetinginflammatorypathwaysandthetumormicroenvironment,aswellasimmunotherapy,mayhavepotentialtherapeuticbenefitsfor